Abstract 1487P
Background
Immune checkpoint inhibitors (ICIs) regimens are the cornerstone of first-line treatment of advanced non-small cell lung cancer (NSCLC).Anlotinib is a multi-targeted tyrosine kinase inhibitor selective for VEGFR, FGFR, PDGFR, and c-kit. The ALTER 0303 trial showed that anlotinib improved both PFS and OS in later-line treatment for advanced NSCLC. Anti-angiogenesis agents has synergistic effect with ICIs. Anlotinib combined with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced NSCLC showed encouraging efficacy and good tolerability. This is an update of the real-world study.
Methods
This is a prospective, multicenter real-world study. The NSCLC cancer patients who received anlotinib in combination with PD-1/PD-L1 inhibitors in first-line or second-line were enrolled. The primary endpoint was PFS, and secondary endpoints were ORR, DCR and OS. The response to treatment was evaluated according to RECIST version 1.1. In addition, adverse events were evaluated by CTCAE v5.0.
Results
From Aug 2021 to May 2023, 147 patients were enrolled in fifteen centers and 104 of them have received at least one tumor assessment. Median age was 66.3 (range:40-84); 82.7% male, 6.7% brain metastasis, 67.3% ECOG PS 1. 60 (57.7%) and 44 (42.3%) patients received anlotinib combined with PD-1 inhibitors as first-line and second-line therapy, respectively. Among all patients, 29 patients were partial response (PR), 72 patients were stable disease (SD), illustrating ORR of 27.9% and DCR of 97.1%. In the first-line, ORR was 30.0%, DCR was 96.6%. In the second-line, ORR was 25.0%, DCR was 97.7%.The median follow-up time was 9.4 months (95%Cl:8.1-10.7). Median PFS and median OS were not reached. The most common Grade 3-4 AEs were decreased lymphocyte count (3.8%), decreased platelet count (2.8%), decreased white blood cells (1.9%), neutropenia (1.9%), hand-foot syndrome (1.0%) and there were no Grade 5 toxicities.
Conclusions
The combination of anlotinib and PD-1/PD-L1 inhibitors may represent a new treatment option as first-line or second-line treatment in advanced NSCLC. The further exploration is ongoing.
Clinical trial identification
ChiCTR 2100049975.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21